Drug evaluation: PRX-00023, a selective 5-HT1A receptor agonist for depression.

Authors
Category Primary study
JournalCurrent opinion in investigational drugs (London, England : 2000)
Year 2007
EPIX Pharmaceuticals Inc (formerly Predix Pharmaceuticals Inc) is developing PRX-00023, an oral aryl piperazine 5-HT1A agonist, for the potential treatment of depression. While initially in development for generalized anxiety disorder, EPIX is now only focusing on the development of PRX-00023 for depression. In November 2006, EPIX reported that it planned to initiate a phase II trial in patients with depression in the first half of 2007.
Epistemonikos ID: 2cc8abe71a54aa35c326dbd882a71372f9c397d8
First added on: Oct 01, 2023